20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Legend Biotech Corp (LEGN) operates in the BIOTECHNOLOGY industry and is headquartered in Somerset, United States with about 3,200 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, LEGN reported $1.0B in revenue and ($297M) in net income.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Interactive charts & full statements → Open the LEGN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.3B | $1.0B | $627M | $285M | $117M | $69M | $75M | $62M | $49M | $24M |
| Gross Profit | $719M | $621M | $393M | $141M | $52M | $69M | $75M | $62M | $49M | $24M |
| Gross Margin % | 56.6% | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.4% |
| Operating Income (EBIT) | ($56M) | ($136M) | ($303M) | ($439M) | ($456M) | ($392M) | ($313M) | ($133M) | ($2M) | $14M |
| Operating Margin % | -4.4% | -13.3% | -48.4% | -154.1% | -389.4% | -570.0% | -417.8% | -214.4% | -3.1% | 58.4% |
| Net Income | ($92M) | ($297M) | ($177M) | ($518M) | ($446M) | ($404M) | ($266M) | ($102M) | ($3M) | $9M |
| Net Margin % | -7.2% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -164.4% | -5.7% | 39.7% |
| EBITDA | ($7M) | ($232M) | ($113M) | ($478M) | ($417M) | ($392M) | ($298M) | ($129M) | $0M | $14M |
| Earnings Per Share (EPS) | $-0.50 | $-1.61 | $-0.97 | $-2.94 | $-2.81 | $-2.87 | $-2.25 | $-0.77 | $-0.03 | $0.07 |
| Shares Outstanding (M) | 194M | 184M | 183M | 176M | 159M | 141M | 118M | 132M | 100M | 132M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $388M | $305M | $306M | $272M | $255M | $195M | $187M | $160M |
| Gross Profit | $250M | $129M | $183M | $157M | $157M | $124M | $113M | $105M |
| Gross Margin % | 64.5% | 42.4% | 59.7% | 57.7% | 61.6% | 63.4% | 60.4% | 65.4% |
| Operating Income (EBIT) | $58M | ($50M) | ($21M) | ($43M) | ($22M) | ($51M) | ($74M) | ($70M) |
| Operating Margin % | 14.9% | -16.3% | -6.7% | -16.0% | -8.6% | -26.0% | -39.9% | -43.7% |
| Net Income | $33M | ($54M) | ($31M) | ($40M) | ($125M) | ($101M) | $26M | ($125M) |
| Net Margin % | 8.6% | -17.8% | -10.1% | -14.6% | -49.2% | -51.7% | 14.1% | -78.2% |
| EBITDA | $60M | ($32M) | ($2M) | ($33M) | ($114M) | ($89M) | $52M | ($110M) |
| Earnings Per Share (EPS) | $0.17 | $-0.29 | $-0.17 | $-0.21 | $-0.68 | $-0.55 | $0.14 | $-0.69 |
| Shares Outstanding (M) | 194M | 185M | 185M | 185M | 184M | 184M | 183M | 183M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($183M) | ($100M) | ($144M) | ($393M) | ($201M) | ($198M) | ($223M) | ($83M) | $308M | ($2M) |
| Capital Expenditures (CapEx) | $73M | $68M | $14M | $23M | $22M | $45M | $30M | $39M | $21M | $1M |
| Free Cash Flow (FCF) | ($256M) | ($168M) | ($158M) | ($416M) | ($224M) | ($244M) | ($253M) | ($122M) | $287M | ($3M) |
| FCF Margin % | -20.1% | -16.3% | -25.2% | -145.9% | -191.1% | -354.3% | -337.7% | -197.8% | 583.4% | -13.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($21M) | ($85M) | ($106M) | $29M | ($13M) | ($104M) | ($82M) | ($76M) |
| Capital Expenditures (CapEx) | $21M | $26M | $21M | $5M | $9M | $2M | $2M | $2M |
| Free Cash Flow (FCF) | ($42M) | ($111M) | ($127M) | $24M | ($22M) | ($106M) | ($84M) | ($78M) |
| FCF Margin % | -10.7% | -36.5% | -41.3% | 8.7% | -8.7% | -54.2% | -45.3% | -48.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.8B | $1.7B | $1.7B | $1.8B | $1.3B | $1.1B | $722M | $288M | $429M | $239M |
| Cash & Cash Equivalents | $673M | $902M | $287M | $1.3B | $786M | $689M | $456M | $83M | $210M | $2M |
| Total Liabilities | $521M | $732M | $630M | $597M | $587M | $354M | $122M | $411M | $420M | $227M |
| Total Debt (Short + Long-Term) | $168M | $326M | $306M | $285M | $264M | $121M | $2M | $1M | $0M | $0M |
| Total Shareholders' Equity | $1.2B | $1.0B | $1.0B | $1.3B | $744M | $766M | $598M | ($123M) | $9M | $12M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LEGN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms